An overview of chemotherapy-induced peripheral neuropathy

Journal of Pharmacy Practice

Volumn 21, Issue 2, 2008, Pages 138-145

  Murillo Jr , Jose R ^a   Cox, James E ^a   Oholendt, Michael S ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Adverse events; Chemotherapy; Neuropathy, peripheral; Neurotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; IMMUNOMODULATING AGENT; IXABEPILONE; LENALIDOMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; THALIDOMIDE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ATAXIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG CLEARANCE; DRUG FORMULATION; DRUG WITHDRAWAL; DYSESTHESIA; HUMAN; HYPERESTHESIA; LHERMITTE DUCLOS DISEASE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; REVIEW; RISK FACTOR; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SINGLE DRUG DOSE;

EID: 44349181902     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008315056     Document Type: Review

References (55)

1. Ocean AJ, Vahdat LT Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004 ; 12: 619-625.
2. Hausheer FH, Schilsky RL, Bain S., Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 ; 33: 15-49.
3. Quasthoff S., Hartung HP Chemotherapy-induced peripheral neuropathy. J Neurol. 2002 ; 249: 9-17.
4. Verstappen CP, Heimans JJ, Hoekman K., Postma TJ Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003 ; 63: 1549-1563.
5. van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, van Houwelingen C., Neijt JP Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer. 1990 ; 66: 1697-1702.
6. Pasetto LM, D'Andrea MR, Rossi E., Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol. 2006 ; 59: 159-168.
7. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004 ; 29: 387-392.
8. Michaud LB, Valero V., Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 2000 ; 23: 401-428.
9. Rowinsky EK, Donehower RC Paclitaxel (Taxol). N Engl J Med. 1995 ; 332: 1004-1014.
10. Mielke S., Sparreboom A., Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimens. Eur J Cancer. 2006 ; 42: 24-30.
11. Guastalla JP, Dieras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer. 2003 ; 89: 16-22.
12. Lee JJ, Swain SM Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006 ; 24: 1633-1642.
13. Seidman AD, Berry D., Cirrincione C., et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol ASCO Annual Meeting Proceedings. 2004 ; 22: 512.
14. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: national surgical adjuvant breast and bowel project B-26. J Clin Oncol. 1999 ; 17: 3403-3411.
15. Mielke S., Sparreboom A., Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res. 2005 ; 11: 4843-4850.
16. Hilkens PH, Verweij J., Stoter G., Vecht CJ, van Putten WL, van den Bent MJ Peripheral neurotoxicity induced by docetaxel. Neurology. 1996 ; 46: 104-108.
17. Dropcho EJ Neurotoxicity of cancer chemotherapy. Semin Neurol. 2004 ; 24: 419-426.
18. Sul JK, DeAngelis LM Neurologic complications of cancer chemotherapy. Semin Oncol. 2006 ; 33: 324-332.
19. Slade JH Neurological toxicities associated with cancer chemotherapeutic agents. US Pharm. 2005 ; 4: 3-18.
20. Plasmati R., Pastorelli F., Cavo M., et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology. 2007 ; 69: 573-581.
21. Apfel SC, Zochodne DW Thalidomide neuropathy: too much or too long. Neurology. 2004 ; 62: 2158-2159.
22. Mileshkin L., Stark R., Day B., Seymour JF, Zeldis JB, Prince HM Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006 ; 24: 4507-4514.
23. Bastuji-Garin S., Ochonisky S., Bouche P., et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol. 2002 ; 119: 1020-1026.
24. Chaudhry V., Cornblath DR, Corse A., Freimer M., Simmons-O'Brien E., Vogelsang G. Thalidomide-induced neuropathy. Neurology. 2002 ; 59: 1872-1875.
25. Velcade [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals Inc ; 2007.
26. San Miguel J., Blade J., Boccadoro M., et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006 ; 11: 51-61.
27. Richardson PG, Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 ; 24: 3113-3120.
28. Oakervee HE, Popat R., Curry N., et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 ; 129: 755-762.
29. Jagannath S., Durie B., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005 ; 129: 776-783.
30. Harousseau JL, Attal M., Leleu X., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006 ; 91: 1498-1505.
31. Badros A., Goloubeva O., Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007 ; 110: 1042-1048.
32. Gupta S., Pagliuca A., Devereux S., Mufti GJ, Schey S. Life threatening motor neuropathy in association with bortezomib. Haematologica. 2006 ; 91: 1001.
33. Ixempra [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company ; 2007.
34. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 ; 25: 5210-5217.
35. Walker M., Ni O. Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol. 2007 ; 30: 82-92.
36. Argyriou AA, Polychronopoulos P., Koutras A., et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy could it be predicted ? Support Care Cancer. 2005 ; 13: 647-651.
37. McDonald ES, Randon KR, Knight A., Windebank AJ Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005 ; 18: 305-313.
38. Rabik CA, Dolan ME Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007 ; 33: 9-23.
39. Heinzlef O., Lotz JP, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998 ; 64: 667-669.
40. Jones SE, Erban J., Overmoyer B., et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005 ; 23: 5542-5551.
41. Boehmerle W., Zhang K., Sivula M., et al. Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation. Proc Natl Acad Sci USA. 2007 ; 104: 11103-11108.
42. Flatters SJ, Bennett GJ Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004 ; 109: 150-161.
43. Persohn E., Canta A., Schoepfer S., et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer. 2005 ; 41: 1460-1466.
44. Freilich RJ, Balmaceda C., Seidman AD, Rubin M., DeAngelis LM Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996 ; 47: 115-118.
45. Gradishar WJ, Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 ; 23: 7794-7803.
46. Plotkin SR, Wen PY Neurologic complications of cancer therapy. Neurol Clin N Am. 2003 ; 21: 279-318.
47. Fazeny B., Zifko U., Meryn S., Huber H., Grisold W., Dittrich C. Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol. 1996 ; 39: 150-156.
48. Briani C., Zara G., Rondinone R., et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology. 2004 ; 62: 2288-2290.
49. Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001 ; 24: 1050-1057.
50. Revlimid [prescribing information]. Summit, NJ: Celgene Corporation Inc ; 2006.
51. Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne HA, Dalgleish AG Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer. 2006 ; 42: 2318-2325.
52. Cavaletti G., Gilardini A., Canta A., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007 ; 204: 317-325.
53. Kannarkat G., Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007 ; 20: 719-725.
54. Gamelin L., Boisdron-Celle M., Delva R., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004 ; 10: 4055-4061.
55. Hochster H., Grothey A., Childs B., et al. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol. 2007 ; 25: 4028-4029.